Ruthenium, dichloro[(1,2,3,4,5,6-η)-1-methyl-4-(1-methylethyl)benzene](1,3,5-triaza-7-phosphatricyclo[3.3.1.13,7]decane-κP7)-
- Structure](CAS/20211123/GIF/372948-28-2.gif)
- CAS No.
- 372948-28-2
- Chemical Name:
- Ruthenium, dichloro[(1,2,3,4,5,6-η)-1-methyl-4-(1-methylethyl)benzene](1,3,5-triaza-7-phosphatricyclo[3.3.1.13,7]decane-κP7)-
- Synonyms
- RAPTA-C;RAPTAC,RAPTA C;Ruthenium, dichloro[(1,2,3,4,5,6-η)-1-methyl-4-(1-methylethyl)benzene](1,3,5-triaza-7-phosphatricyclo[3.3.1.13,7]decane-κP7)-
- CBNumber:
- CB010715729
- Molecular Formula:
- C16H23Cl2N3PRu
- Molecular Weight:
- 460.32
- MDL Number:
- MOL File:
- 372948-28-2.mol
Ruthenium, dichloro[(1,2,3,4,5,6-η)-1-methyl-4-(1-methylethyl)benzene](1,3,5-triaza-7-phosphatricyclo[3.3.1.13,7]decane-κP7)- Chemical Properties,Uses,Production
Description
RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways.
Uses
RAPTA-C (Ru(η6-p-cymene)Cl2(pta)) acts as an anti-cancer and anti-angiogenic agent. RAPTA-C exhibits anti-metastatic, anti-angiogenic, and anti-tumoral activities through protein and histone-deoxyribonucleic acid alterations. RAPTA-C exhibits cell growth inhibition by triggering G(2)/M phase arrest in cancer cells. RAPTA-C also enhances the levels of p53 and triggers the mitochondrial Apoptotic pathway, resulting in cytochrome C release and caspase-9 activation. RAPTA-C reduces the growth of tumors with the inhibition of angiogenesis in a ovarian carcinoma model[1][2][3].
References
[1] Rausch M, et al. Recent considerations in the application of RAPTA‐C for cancer treatment and perspectives for its combination with immunotherapies[J]. Advanced Therapeutics, 2019, 2(9): 1900042.
[2] Weiss A, et al. In vivo anti-tumor activity of the organometallic ruthenium (II)-arene complex [Ru (η 6-p-cymene) Cl 2 (pta)](RAPTA-C) in human ovarian and colorectal carcinomas[J]. Chemical Science, 2014, 5(12): 4742-4748.
[3] Chatterjee S, et al. The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J Biol Inorg Chem. 2008 Sep;13(7):1149-55. DOI:10.1007/s00775-008-0400-9
Ruthenium, dichloro[(1,2,3,4,5,6-η)-1-methyl-4-(1-methylethyl)benzene](1,3,5-triaza-7-phosphatricyclo[3.3.1.13,7]decane-κP7)- Preparation Products And Raw materials
Raw materials
Preparation Products
Ruthenium, dichloro[(1,2,3,4,5,6-η)-1-methyl-4-(1-methylethyl)benzene](1,3,5-triaza-7-phosphatricyclo[3.3.1.13,7]decane-κP7)- Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | support@targetmol.com | United States | 38663 | 58 | |
| Wuhan Han Sheng New Material Technology Co.，Ltd | +8617798174412 | admin01@hsnm.com.cn | China | 2097 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11973 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 19965 | 58 |
| Sangon Biotech (Shanghai) Co.,Ltd. | 400-821-026 | Sales@sangon.com | China | 55710 | 58 |